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DISSERTATION ON PREVELANCE OF ANTI TPO ANTIBODY IN 
INSULIN DEPENDENT DIABETES IN A TERTIARY CARE CENTRE
INTRODUCTION                                                                 
There are a number of auto antibodies associated with the auto
immune thyroid diseases, which are characterized as either primary or secondary antibodies. 
Primary  antibodies  are  directly  pathogenic  and  often  directed  against  cell  membrane 
receptors, whilst secondary antibodies do not appear to be involved in pathogenesis but can 
serve as a useful diagnostic marker for the presence of autoimmune thyroid disease. Thyroid 
peroxidase  (TPO)  antibodies  are  one  of  the  major  secondary  antibodies  associated  with 
autoimmune thyroid disease. 
TPO was previously known as thyroid microsomal antigen. It is a 
107 KD enzyme which is involved in thyroid hormone synthesis. TPO is located both on the 
cell  surface  and within  the  cytoplasm of  thyroid  acinar  cells,  bound to  the  vesicle  which 
transports  newly  synthesized  thyroglobulin,  where  it  is  involved  in  the  iodination  of 
thyroglobulin. High affinity antibodies (predominantly IgG)  directed against TPO is found at 
elevated levels in the serum of patients with autoimmune thyroid disease such as Graves’s 
disease,  Hashimoto’s  thyroiditis,  Diabetes  mellitus  and  myxoedema.Autoimmune  thyroid 
disease (AITD) causes cellular damage and alters thyroid gland function by humoral and cell-
mediated mechanisms. 
Cellular damage occurs when sensitized T-lymphocytes and/or
auto antibodies bind to thyroid cell membranes causing cell lysis and inflammatory reactions. 
Alterations in  thyroid  gland function result  from the action of  stimulating or  blocking auto 
antibodies on cell membrane receptors. Three principal thyroid auto antigens are involved in 
AITD. These are thyroperoxidase (TPO),thyroglobulin (Tg) and the TSH receptor. Other auto 
antigens, such as the Sodium lodide Symporter (NIS) have also been described, but as yet 
have no diagnostic role in thyroid autoimmunity.  
CLINICAL SIGNIFICANCE OF THYROID AUTOANTIBODIES
TPO antibodies (TPOAb) appear to be involved in the tissue destructive processes 
associated  with  the hypothyroidism observed in  Hashimoto’s  and atrophic  thyroiditis.  The 
appearance  of  TPOAb  usually  precedes  the  development  of  thyroid  dysfunction.  Some 
studies  suggest  that  TPOAb  may  be  cytotoxic  to  the  thyroid.  TPOAb  and/or  TgAb  are 
frequently present in the sera of patients with AITD.
The prevalence of thyroid auto antibodies is increased when patients have non-thyroid 
autoimmune  diseases  such  as  type  1  diabetes  and  pernicious  anemia.  Ageing  is  also 
associated with the appearance of thyroid auto antibodies and increased prevalence of AITD.
 
THYROID DISEASE AND DIABETES:      
Thyroid  disease  is  widespread  and  prevalence  increases  with  advancing  age. 
However, as assessing thyroid function is reliable and inexpensive, certain high risk groups- 
such as neonates, the elderly and diabetics – should undergo regular screening.
   Diabetes mellitus (DM) is a multisystem disease with both biochemical and anatomical 
consequences. It is a chronic disease of carbohydrate, fat, and protein metabolism caused by 
the lack of insulin. In type 1 diabetes, insulin is functionally absent because of the destruction 
of the beta cells of the pancreas. Type 1 DM occurs most commonly in juveniles but can 
occur in adults, especially in those in their late 30s and early 40s.
Diabetes mellitus is thought to be, in some cases, an auto-immune disease caused 
when antibodies attack certain cells of the pancreas, affecting the production of insulin. In 
patients or families where auto-immune thyroid disease exists, this type of diabetes mellitus 
may develop, sometimes in younger members of the family. 
This  should  be  suspected  particularly  if  symptoms of  tiredness  and  weight  loss  develop 
together with increased thirst and passing of large volumes of urine.
Clinically,  thyroid  dysfunction  may  undermine  diabetes  control.  For  example, 
hyperthyroidism may worsen  glycemic  control  and  increase  insulin  requirements.  Indeed, 
thyrotoxicosis may unmask subclinical diabetes.
While  hypothyroidism markedly  alters  carbohydrate  metabolism,  such  changes  are 
rarely  clinically  significant.  However,  as  less  insulin  is  degraded,  the  exogenous  insulin 
requirement  may  be  lower.  Moreover,  hypothyroidism  often  produces  dyslipidaemias, 
including elevated triglyceride and low- density lipoprotein (LDL) cholesterol concentrations. 
Therefore,  hypothyroidism  can  exacerbate  coexisting  dyslipidaemias  in  type  2  diabetes. 
Thyroxine  reverses  these lipid  abnormalities.  That  diagnosing  thyroid  dysfunction  can be 
difficult. For example, poor glycaemic control produces symptoms similar to hyperthyroidism, 
such as weight  loss despite  increased appetite  as well  as fatigue.  Clinicians need to  be 
careful not to confuse severe diabetic nephropathy and hypothyroidism: both produce edema, 
fatigue, pallor and weight gains. Finally, poorly controlled diabetes may alter thyroid function.
Against  this  backround,  the serum TSH immunoassay offers the most  reliable  and 
sensitive  screening  test  for  thyroid  dysfunction.  However,  screening  for  anti-thyroid 
peroxidase (TPO) antibodies in people with type 1 diabetes may predict autoimmune thyroid 
disorders.
Management is generally similar to that in the non-diabetic population. However, L-
thyroxine therapy may exacerbate angina by increasing myocardial  contractility and heart 
rate.  Clinicians  should  consider  treating  subclinical  hypothyroidism if  patients  either  have 
elevated serum LDL cholesterol  exacerbated by hypothyroidism or detectable serum anti-
TPO antibodies.
Thyroid dysfunction is common among diabetic patients and can produce metabolic 
disturbances. Therefore, regularly screening diabetic patients allows early treatment. Type 1 
patients expressing anti-TPO antibodies should be screened annually. In anti-TPO negative 
patients, a TSH assay every two to three years suffices. Among patients suffering from type 2 
diabetes, clinicians should consider a TSH at diagnosis and then at least every five years.
BIOCHEMISTRY OF THYROID PEROXIDASE (TPO)  
Thyroid Peroxidase (TPO) is a 110 KD membrane bound hemo-glycoprotein with a 
large extracellular  domain, and a short   transmembrane and intracellular  domain. TPO is 
involved in thyroid hormone synthesis at the apical pole of the follicular cell. Several isoforms 
related to differential splicing of TPO RNA have been described. TPO molecules may also 
differ  with  respect  to their  three dimensional  structure ,  extent of  glycosylation and heme 
binding. Most of the TPO molecules do not reach the apical membrane and are degraded 
intracellularly.
The human thyroid peroxidase (TPO) found in  the thyroid  follicular  cells,  is  a high 
molecular weight glycoprotein containing hem prosthetic group. It plays a central role in the 
multi-step biosynthesis of thyroid harmones, T4 and T3.
Thyroid disorders are caused in most cases due to the production of auto-antibodies 
against different antigens of thyroid tissues. Most important auto-antibodies are those against 
thyroglobulin, thyroid peroxidase and the TSH receptor.
Anti-TPO is found in all thyroid autoimmune diseases, with the highest level observed 
in  Hashimoto’s  thyroiditis.  Elevated  concentration  of  anti-TPO  is  also  characteristic  of 
idiopathic myxedema and chronic atrophic thyroiditis. Anti-TPO auto-antibodies are regarded 
as the indicator of developing thyroiditis during pregnancy, or in patients with familiar history 
of different autoimmune diseases (Type-1 diabetes mellitus, Addison’s disease, pernicious 
anemia) . 
 
OBJECTIVE OF THE STUDY
1. To detect and measure TPO – Ab in young IDDM individuals.
2. To find out the Thyroid abnormalities in TPO – Ab positive individuals in IDDM – 
using Thyroid function tests.
REVIEW OF LITERATURE
1) Hiroki Shimura et al auto immune endocrine diseases occur most frequently among 
various auto immune diseases. Type-1 DM & Grave’s disease frequent in daily clinical 
practice. Auto immune mechanism are involved in many cases of Type-1DM Which 
ranging from rapid onset and slowly progresses over years.
2) Hiltunen during their study of immunization and Type- 1 diabetes mellitus found that 
there is no clear evidence of either to prevent or to induce diabetes in human.
3) PK.Moulik et al  on their study of patients with diabetes who previously had thyroid 
function test found that 11% were TPO(+).
4) Guillermo and his colleagues during their cross-sectional studies in Type I diabetes 
confirms the association between auto immune thyroid disfunction and Type I diabetes. 
Patients who were TPO (+) 17.91 times likely to develop hypothyroidism. Their were no 
differences in BMI, Lipid profile between patients with (or) without thyroid disfunction. 
They conclude all subjects with Type I diabetes should undergo annual screening by 
TSH measurement to detect asymptamatic thyroid disfunction with (+) TPO antibody.
5) Kordonouri O et al in a multi-center survey found out that 21.6% elevated levels of anti 
TPO levels .Thyroid auto immunity more common in girls.
6) Prazny et al in their study on auto immunity in Type I DM with respect to diabetes 
control have found that auto antibodies in Type I diabetes patients could reveal sub-
clinical  cases  of  AITD.  They have  no  influence  on  diabetic  control.  They suggest 
proper follow up of patients with positive auto antibodies.
7) H.G Bohnet found that use of cord blood is an alternative form to screen anti TPO.
8) A multi center survey conducted by Olga Kordonouri et al on Thyroid auto immunity in 
children and adolescent with Type I diabetes found out 15.4% had raised anti TPO. 
Girls have more antibodies than boys. Measurement of anti TPO and TSH in yearly 
intervals after the age of twelve.
9) D.Hansen et al in a study on Thyroid function morphology and auto immunity in young 
patients with IDDM have found that there were no significance differences in Thyroid 
function variables.
10)A  longitudinal  study  of  first  degree  relations  of  Type  I  diabetes  patients  by 
E.Hatziagelakil  et al found that thyroid auto immunity has to be tested regularly not 
only in diabetic but also in their first degree relatives.
11)I.H.De Leeuw done a cross-sectional study found that auto immune aggression is not 
limited  to  the  pancreas  but  also  to  the  other  endocrine  systems  (Thyroid)  were 
frequently found to  be increased in  Type I  DM patients  as  compared non-diabetic 
populations.
12)Y.Vainilovich et al during their study over to adolescent with Type I DM with a duration 
of 5 – 15 years found that TPO AB increased in 13.7% and there is no correlation 
between duration of diabetes and TPO AB.
13)Immuno assay of anti thyroid auto antibodies by Renato Tozzoloi et at suggested that 
the use of high sensitive immuno metric methods in clinical laboratories to assay anti 
thyroid antibody has expanded.
14)Bilimoria and his colleagues on analyzes of Type I diabetes with auto immune thyroid 
disfunction  found  that  TPO  and  TSH  measurements  are  the  most  efficient  cost 
effective combination of screening test.
15)D.Hansen et al on their prospective study of Thyroid function and auto immunity in 
young patients with Type I  diabetes found that prevalence of TPO Ab at 13% and 
recommend screening using serum TSH in follow up of young diabetic patients.
16)A study on IDDM and auto immune thyroid disease in the Pediatric age group by Lorini 
et al found that screening for auto immunity even if the patients are asymptamatic. 
AITD is frequently associated with IDDM ant the presence of Thyroid auto antibody has 
been considered as a risk factor for the development of hypo (or) hyper thyroidism.
17)K.F.Tait et al on their study found that females are more frequently affected by auto 
immune disease particularly AITD.
18)Natural course of auto immune thyroiditise in Type I diabetes: association with gender, 
age, diabetes duration and puberty – study conducted by O.Kardonouri et al found that 
among diabetes17 had TPO AB, which may be used as a marker of  Thyroid auto 
immunity.
19)Jin P et al in their study on adult onset latent auto immune diabetes and AITD found 
that 16% TPO Ab present in latent auto immune diabetes. The presence of Thyroid 
antibody may predict high risk of thyroid dysfunction.
20)J.C.Blair and J.Allgrove proposed a screening protocol for thyroid dysfunction co-exist 
with Type I diabetes thyroid function should be assessed annually in diabetic children. 
Thyroid auto antibodies are measured at diagnosis and repeated if TSH level raised.
21)A study done by Kalicka kasper czyk et al on TPO antibodies and thyroid diseases in 
children and adolescent with Type I diabetes mellitus found positive TPO Ab titer in 
34.7% patients. 5% patients shows thyroid dysfunction.
22)De louis da et al conducted a study on in Type I patients with their families concludes 
value of TPO Ab were higher in patients than families. No correlation between auto 
immunity and glycemic control.
23)In the diabetic volume study of the predictivity of thyroid auto antibodies in children and 
adolescents with Type I diabetes found that 10% of anti-TPO. Girls had mere elevated 
anti-TPO. They conducted that 50% of children with diabetes and significant titres of 
anti-TPO – Ab.
24)Erin McCanlies et al during the study of Hashimoto’s thyroiditis and insulin dependent 
diabetes mellitus suggested that gender risk factors may be primary determinants of 
Hashimoto’s thyroiditis and other auto immune diseases among women.
25)Czerniawska E, Szalecki et al  during the study on prevalence of thyroid antibodies 
TPO and ATGaE the onset  of  Type I  diabetes mellitus in children found that  auto 
immune Type I DM other organ specific antibodies particularly thyroid auto antibodies. 
TPO antibodies were 17.8% of children and in 19.2% of other centers.
26)Laurberg and his colleagues in the study on sensitive enzyme linked immunosorbent 
assay for measurement of auto antibodies to human thyroid peroxidase found that auto 
antibodies against  TPO containing 70,7,07,0.02 and 0 uml-1.The new method is  a 
valuable tool for studying the epidemiology of thyroid auto immunity.
MATERIALS AND METHODS
Since the onset of insulin dependent diabetes which occurs in earlier years who 
were only on insulin therapy without any anti-thyroid (or) hormone (or) lipid lowering drugs. 60 
persons were selected for this study.
This study was conducted at Tertiary Care Medical Centre, Thanjavur Medical 
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5.To rule out features suggesting any hypo (or) hyper thyroid     
    Status.
Fasting  blood  specimen was  collected  from each participant  plasma fasting 
glucose level were estimated GOD/POD method by auto analyzer.
Serum triiodo thyronine, serum thyroxine and thyroid stimulating hormone  were 
estimated by enzyme immuno assay method.
Serum  total  cholesterol,  serum  triglycerides,  serum  low  density  lipo  protein 
cholesterol  and serum high  density  lipo  protein  cholesterol  were  estimated in  the  fasting 
serum sample.
ESTIMATION OF TPO ANTIBODIES BY ACCUBIND ELISA MICROWELLS
PRINCIPLE
A SEQUENTIAL ELISA METHOD
The  reagents  required  for  the  sequential  ELISA  assay  include  immobilized 
antigen,  circulating  autoantibody  and  enzyme-linked  species-specific  antibody.  In  this 
procedure, the immobilization takes place during the assay at the surface of a microplate well 
through the interaction of streptavidin coated on the well and exogenous added biotinylated 
thyroid peroxidase antigen.
Upon  mixing  biotinylated  antigen  and  a  serum containing  the  autoantibody, 
reaction  results  between the  antigen and the  antibody to  form an immune-complex.  The 
interaction is illustrated by the followed equation:
                                                          k a
h-Ab(X-TPO)   +   BtnAg(TPO)                       h-Ab(X-TPO)    -   BtnAg(TPO)
               k -a
BtnAg(TPO)        = Biotinylated Antigen (Constant Quantity)
h-Ab(X-TPO)     =  Human Auto-Antibody (Variable Quantity)
Ab(X-TPO)    -   BtnAg(TPO)  =  Immune Complex (Variable Quantity)
k a = Rate Constant of Association
k -a  = Rate Constant of Disassociation
Simultaneously, the complex is deposited to the well through the high affinity 
reaction of streptavidin and biotinylated antigen. This interaction is illustrated below:
h-Ab(X-TPO)    -   BtnAg(TPO) + Streptavidin c.w  ⇒ immobilized complex (IC) 
   
Streptavidin c.w    = Streptavidin immobilized on well
Immobilized complex  = sandwich complex bound to the solid surface
After  the  incubation  time,  the  well  is  washed  to  separate  the  unbound 
components by aspiration and /or decantation. The enzyme linked species-specific antibody 
(anti-h-IgG) is then added to the microwells. This conjugates binds to the immune complex 
that formed.
IC (h-IgG) + ENZ Ab(X- h-IgG)           ENZ Ab(X- h-IgG) -  IC (h-IgG)
IC (h-IgG) = Immobilized Immune Complex (Variable Quantity)
ENZ Ab(X- h-IgG) = Enzyme-antibody conjugate (Constant Quantity)
ENZ Ab(X- h-IgG) -  IC (h-IgG) = Antigen –Antibody Complex (Variable Quantity)
The anti-h-lgG enzyme conjugate that binds to the immune complex in a second 
incubation is separated from unreacted materials to the reacted materials which is directly 
proportional to the antibody concentration in the specimen. By utilizing several different serum 
references of known antibody activity, a reference curve can be generated from which the 
antibody activity of an unknown can be ascertained.
REAGENTS:
A. Anti-TPO Calibrators – 1.0 ml/vial – Icons A-F
Six (6) vials of references for anti-TPO at levels of 0(A),25(B),50(C),100(D),250(E) and 
500(F) IU/ml. Store at 2-8°C.A preservative has been added.
B. TPO Biotin Conjugate -13ml/vial – Icon 
One  (1)  vial  of  biotinylated  thyroid  peroxidase  antigen  in  a  buffering  matrix.  A 
preservative has been added. Store at 2-8°C.
C. Enzyme-antigen Conjugate -13ml/vial – Icon 
One (1) vial of anti-human lgG-horseradish peroxidase (HRP) conjugate in a buffering 
matrix. A preservative has been added. Store at 2-8°C.
D. Streptavidin Coated Microplate -96 wells – Icon 
One 96-well  microplate coated with streptavidin and packaged in an aluminum bag 
with a drying agent. Store at 2 - 8°C.
E. Serum Diluent Concentrate -- 20 ml
One (1) vial of serum diluent containing buffer salts and a dye. Store at 2 - 8°C.
F. Wash Solution Concentrate -- 20ml – Icon 
One (1) vial containing a surfactant in buffered saline. A preservative has been added. 
Store at 2 - 8°C.
G. Substrate A – 7ml/vial – Icon  S A
One (1) bottle containing tetramethylbenzidine (TMB) in buffer. Store at 2 - 8°C.
H. Substrate B – 7ml/vial – Icon S B
One (1) bottle containing hydrogen peroxide(H2O2) in buffer. Store at 2 - 8°C.
I. Stop Solution – 8ml/vial – Icon  
One (1) bottle containing a strong acid (1 N HCl). Store at 2 - 8°C.
REAGENT PREPARATION:
1. Serum Diluent
Dilute the serum diluent concentrate to 200ml in a suitable container with distilled or 
deionized water. Store at 2 - 8° C.
2. Wash Buffer
Dilute contents of Wash Concentrate to 1000ml with distilled or deionized water in a 
suitable storage container. Store at room temperature 20-27° C for up to 60 days.
3. Working Substrate Solution
Pour the contents of the vial labeled Solution ‘A’ into the vial labeled Solution ‘B’. Mix 
and store at 2-8° C. Use within 60 days. Or for longer periods of usage determine the 
amount of reagent needed and prepare by mixing equal portions of Substrate A and 
Substrate B in a suitable container. For example, add 1ml of A and 1ml of B per two (2) 
eight well strips (A slight excess of solution in made. Discard the unused portion).
           Note: Do not use the working substrate if it looks blue.
4. Patient Sample Dilution (1/100)
Dispense 0.010ml (10µl) of each patient specimen into 1ml of serum diluent. Coverand 
vortex or mix thoroughly by inversion. Store at 2-8° C for up to forty-eight (48) hours.
TEST  PROCEDURE: Before  proceeding  with  the  assay,  bring  all  reagents,serum 
references and controls to room temperature (20-27° C).
1. Format the microplant wells for each serum reference, control and patient specimen to 
be assayed in duplicate.Replace any unused microwell strips back into the aluminum 
bag, seal and store at 2-8°C.
2. Pipette 0.025 ml (25µl) of the appropriate serum reference,control or diluted patient 
specimen into the assigned well.
3. Add 0.100 ml (100µl) of TPO Biotinylated Conjugate Solution.
4. Swirl the microplate gently for 20-30 seconds to mix and cover.
5. Incubate 60 minutes at room temperature.
6. Discard the contents of the microplate by decantation or aspiration. If decanting, blot 
the plate dry with absorbent paper.
7. Add 300µl of wash buffer (see Reagent Preparation Section), decant (blot and tap) or 
aspirate. Repeat two(2) additional times for a total of three (3) washes. An automatic or 
manual  plate  washer  can be used.  Follow the manufacture’s  instruction  for  proper 
usage.  If  a  squeeze bottle  is  employed,  fill  each well  by depressing the container 
(avoiding air  bubbles)  to  dispense the wash.  Decant  the wash and repeat  two (2) 
additional times.
8. Add 0.100 ml (100µl) of enzyme anti-h-lgG Conjugate Solution to all wells. Always add 
reagents in the same order to minimize reaction time differences between wells.
9. Swirl  the  microplate  gently,  cover  and  incubate  for  thirty  (30)  minutes  at  room 
temperature.
10.Repeat steps  (6&7) as explained above.
11.Add  0.100  ml  (100µl)  of  Working  Substrate  Solution  to  all  wells  (see  Reagent 
Preparation Section). Always add reagents in the same order to minimize reaction time 
differences between wells.
12. Incubate at room temperature for fifteen (15) minutes.
13.Add 0.050ml (50 µl) of stop solution to each well and mix gently for 15-20 seconds. 
Always add reagents in the same order to minimize reaction time differences between 
wells.
14.Read  the  absorbance  in  each  well  at  450nm  (using  a  reference  wavelength  of 
620-630nm to minimize well imperfections) in a microplate reader. The results should 
be read within thirty (30) minutes of adding the stop solution.
Normal TPO – Ab level – Below Forty (40) IU / ml 
ESTIMATION OF T3 BY ELISA METHOD
PRINCIPLE
In the Biotecx OptiCoat™ T3 EIA kit, antibody to T3 (produced in New Zealand 
white rabbits by administration of T3 that was coupled to a protein carrier), is the specific 
antibody immobilized on microwell plates. Purified T3 conjugated to the enzyme horseradish 
peroxidase  (HRP),  is  used  to  detect  T3.  In  order  to  accurately  measure  the  Total  T3 
concentration  in  serum,  the  endogenous  binding  proteins  (i.e.,  TBG,  albumin  and 
prealbumin ) are blocked by the use of 8-anilino-1-naphthalene sulfonic acid (ANS).
In the assay procedure, the T3 standard and/or patient serum is added along 
with  T3-horseradish  peroxidase  conjugate  to  the  antibody  coated  wells.  A  competition 
reaction results between the native antigen in the serum, and the enzyme-antigen conjugate 
for a limited number of solid phase binding sites. After equilibrium is attained, the antibody-
bound  fraction  is  separated  from  unbound  antigen  in  a  washing  step  by  decantation  or 
aspiration. 
Enzyme substrate 3,3’,5,5’-Tetramethylbenzidine (TMB) is then added to the 
microwell  and incubated.  In  the presence of  conjugate-antigen-antibody complex,  TMB is 
hydrolyzed to a colored end product.
The enzyme activity in the antibody-bound fraction as measured by the intensity 
of the color development is inversely proportional to the native antigen concentration. The 
intensity of color is measured spectrophotometrcally at 450 nm. The concentration of T3 is 
interpolated from a standard curve. The concentration of T3 in a given specimen, determined 
with assays from different manufactures, can vary due to differences in assay methods and 
reagent specification.
1.MICROWELL PLATE: Cat.No.BL 4310,1 plate of 96 wells
Microwell plates are coated with rabbit T3 antibody.Store bag
with microwell plateat 2-8 °C. Allow bag to come to room temperature prior to opening. Once 
the bag is opened, the microwell strips should be resealed and stored in the bag with the 
dessicant. When stored in this manner the breakaway wells are stable until the date indicated 
on the kit.
2.T3 CONJUGATE: Cat.No.BL 4320,10 mL
Horseradish peroxidase conjugated to triiodothyronine in a buffered solution, 
containing bovine serum albumin, inhibitors, and preservatives.
3.OneBlue™, TMB Single Substrate:Cat.No.BL 29932,22mL
Contains 3,3’,5,5’- Tetramethylbenzidine substrate reagent in a stabilized buffer 




Six vials, T3 standards 0,50,100,250,500 and 1000 ng/dL, in T3 free human 
serum with thimerosal added as a preservative.
6.CONTROL SERUM (Lyophilized):Cat.No.BL 2680
Contains human serum and preservative. Reconstitute with 1mL
of distilled water. Storage:Freeze at -15° C. Three tested cycles of freezing and thawing had 
no effect on T3 concentration.Stability: When stored, 1 year from date of reconstitution at -15° 
C
7.WASH SOLUTION CONCENTRATE:Cat.No.BL 21-138, 15mL
Buffer solution concentrate with thimerosal added as a preservative. Prepare 
working wash solution by adding the 15mL Wash Solution Concentrate to 500ml of distilled 
water. Store at 2-8° C. The working buffer in stable until the expiration of the kit.
REAGENT PREPARATION:
1. STANDARDS,CONTROL SERUM, AND PATIENT SPECIMEN.
Ensure that the reagents are at room temperature prior to use.
2. SAMPLE PREPARATION,STORAGE, AND HANDLING
Collect  a minimum of 0.5mL of whole blood. Allow blood to clot,  and separate the 
serum. Specimens can be stored for short-term (1day) at 2-8° C or for long-term at -20 
Grossy hemolyzed, contaminated, lipemic,specimens and samples containing bilirubin 
should not be used. Avoid repeated freeze-thaw of samples. In the case of frozen 
samples, be sure to thaw samples completely before use.
3. STORAGE OF KIT
The kit should be stored at 2-8° C. Do not freeze. Allow reagents to come to room 
temperature  prior  to  use.  Ensure  that  the  microwell  bag  is  sealed  well  with  the 
dessicant. Failure to do so can result in deterioration of the antibody-coated wells.
TEST PROCEDURE
Remove  the  appropriate  number  of  microwell  strips  from the  bag.  Ensure  that  all 
unused  strips  remain  in  the  bag,  and  that  the  bag  is  sealed  well,  and  returned  to  the 
refrigerator. Include two wells each for the standards, control serum, and test sample(s).
1. Add 50 µL each of Standards, Control Serum, and Test sample(s) in the appropriate 
wells.
2. Add 2 drops or 100 µL of T3-Conjugate to each well.  Complete additions within 5 
minutes. Cover the plate. Mix wells by swirling the plate gently for 30 seconds and 
incubate at room temperature(22-25°C) for 1 hour.
3. Decant or aspirate the supernatant from all the wells. Drain thoroughly by inverting the 
plate and tapping vigorously on an absorbent paper towel to remove excess fluid.
4. Wash the wells  five times with  diluted wash solution.  After  each wash,  completely 
empty the wells as described above.
5. Add 4 drops or 200 µL of OneBlue TMB-Substrate solution to each well. Mix wells by 
swirling the plate gently for 30 seconds. Complete all additions within 5 mintues. Cover 
the plate and incubate at room temperature (22-25°C) for 30 mintues.
6. Add 2 drops or  100 µL of  Stop Solution to  each well.  Tap gently to  mix the stop 
solution. Avoid splashing.
7. Read the absorbance at 450 nm.
Normal T3 – 77 to 207 ng/dl
ESTIMATION OF TOTAL THYROXINE T4 –BY ELISA
PRINCIPLE
Specific anti-T4 antibodies are coated onto microtitration wells. Test sera are applied. 
T4  with  Horseradish  peroxide  enzyme  (Conjugate)  is  added  which  competes  with  the 
released serum T4 for available binding sites on the solid phase.
After incubation, the wells are washed with water to remove any unbound T4 or T4 
enzyme conjugate. On addition of the Substrate(TMB), a colour develops only in those wells 
in which enzyme is present, indicating a lack of serum T4. 
The reaction is stopped by the addition of dilute Sulphuric Acid and the absorbance in 
then measured at 450nm. This test has been callbrated against in house standards. There is 
no international standard for the test.
CONTENTS:
Microtitre Plate 12 * 8 Wells * 1
Breakable  wells  coated  with  specific  antibodies 
contained in a reseal able foil bag with a desiccant
Cal A 0 ng/ml 1 ml
Reference Standard: Human serum free of T4. Ready 
to use. (Colourless)
Cal B 20 ng/ml 1 ml
Reference  Standard:  T4  diluted  in  human  serum. 
Ready to use. (Colourless)
Cal C 50 ng/ml 1 ml
Reference  Standard:  T4  diluted  in  human  serum. 
Ready to use. (Colourless)
Cal D 100 ng/ml 1 ml
Reference  Standard:  T4  diluted  in  human  serum. 
Ready to use. (Colourless)
Cal E 150 ng/ml 1 ml
Reference  Standard:  T4  diluted  in  human  serum. 
Ready to use. (Colourless)
Cal F 250 ng/ml 1 ml
Reference  Standard:  T4  diluted  in  human  serum. 
Ready to use. (Colourless)
Control Level as stated on vial 1 ml
Known level of T4 diluted in human serum. Ready to 
use. (Colourless)
Washbuf 20X 50 ml
Wash Buffer concentrate : Tris based buffer containing 
detergents. (Colourless)
Conj 11X 1.3 ml
T4  HRP  conjugate  concentrate:  T4  Conjugated  to 
Horseradish Peroxidase. (Colourless)
DIL Conj 12 ml
Conjugate Diluent:Phosphate based buffer containing 
stabilizing proteins. Working Strength(Green)
Subs TMB 11 ml
Substrate Solution: 3,3’,5,5’TetramethylBenzidine in a 
citrate buffer.Ready to use. (Colourless)
Soln Stop H2SO4 0.2M 11 ml
Stop Solution: Sulphuric Acid diluted in purified water. 
Ready to use. (Colourless)
REAGENT PREPARATION:
All reagents should be brought to room temperature (20°C to 25°C) and mixed gently 
prior to use. Do not induce foaming.
Conjugate: Dilute the concentrated conjugate using 1 part concentrated  conjugate with 10 
parts conjugated diluent.eg Add 0.1 ml concentrated conjugate to 1.0 ml of conjugate diluent. 
This  should  be  done  20  minutes  prior  to  initiation  of  the  assay.  Ensure  that  the  diluted 
conjugate is at room temperature. Do not induce foaming. Use within 24 hours.
Only  prepare  sufficient  working  strength  conjugate  solution  to  perform  the 
assays  required  for  that  day.  i.e.,  2  strips  of  8  wells  will  require  160 µl  of  concentrated 
conjugate diluted in 1.6 ml of conjugate diluent.
Wash Buffer: Dilute the concentrated Wash Buffer using 1 part Wash Buffer concentrate with 
19 parts distilled water. For every 8-well breakable strip, prepare 25ml of diluted Wash Buffer 
by adding 1.25ml of concentrated Wash Buffer to 23.75ml of distilled water. Prepare fresh 
diluted Wash Buffer prior to every assay run. Extra Wash Buffer is supplied to enable priming 
of automatic washing machines.
The  washing  procedure  is  critical  to  the  outcome  of  this  test.  Insufficient 
washing will result in poor precision and falsely elevated absorbance readings.
ASSAY PROCEDURE
1. Bring all the kit components and the test serum to room temperature (20°C to 25°C) 
prior to the start of the assy.
2. One set of Standards should be run with each batch of test serum. Secure the desired 
number of coated wells in the holder. Record the position of the standards and the test 
serum on the EIA Data Recording Sheet Provided.
3. Unused strips should be resealed in the foil bag containing the desiccant, using the 
resealing zip-lock before being replaced at 2°C to 8°C .
4. Dispense 25µl of Standards and test serum into the assigned wells.
5. Dispense 100 µl of working strength conjugate into each well.
6. Thoroughly mix for 30 seconds. It is very important to mix completely in this step.
7. Incubate of 60 minutes at room temperature (20°C to 25°C).
8. At the end of the incubation period, discard the contents of the wells by flicking plate 
contents into a Biohazard container. Then strike the wells sharply against absorbent 
paper. Ensure adequate disinfectants is contained in the Biohazard container.
9. Hand Washing: Fill the wells with a minimum of 300 µl of wash buffer per well. Flick 
plate  contents  into  a  Biohazard  Container.  The  strike  the  wells  sharply  against 
absorbent paper. Wash the empty wells 5 times.
10.Strike the wells sharply onto absorbent paper or paper towel to remove all  residual 
water droplets.
11.Machine Washing: Ensure that 300 µl of wash buffer is dispensed per well and that an 
appropriate disinfectant is added to the waste collection bottle. Wash the empty wells 5 
times. After washing remove excess fluid by striking the wells sharply onto absorbent 
paper or paper towel to remove all residual water droplets.
12.Dispense 100 µl Substrate Solution into each well and mix gently for 5 seconds.
13. Incubate in the dark for 20 minutes at room temperature (20°C to 25°C)
14.Stop the reaction by adding 100 µl Stop Solution to each well.
15.Gently mix for 30 seconds to ensure that the blue colour changes completely to a 
yellow colour.
16.Read the optical  density immediately (no later that  10 minutes) using a microplate 
reader with a 450nm filter.
Normal T4 – 5 to 12 µg/dl
ESTIMATION OF THYROID STIMULATING HORMONE BY ELISA
PRINCIPLE 
Specific anti-TSH antibodies are coated onto microtitration wells. Test sera are applied. 
Then goat anti-TSH labelled with Horseradish Peroxidase enzyme (Conjugate) is added. If 
human TSH is present in sample it will combine with the antibody on the well and the enzyme 
Conjugate, resulting in the TSH molecule being sandwiched between the solid phase and the 
enzyme linked antibodies. After incubation, the wells are washed to remove unbound labelled 
antibodies. On addition of the Substrate (TMB), a colour will develop only in those wells in 
which  the  enzyme  Conjugate  is  present,  indicating  the  presence  of  TSH.  The  enzyme 
reaction is stopped by the addition of dilute Hydrochloric acid and the absorbance is then 
measured at 450nm.
The  test  has  been  calibrated  to  the  NIBSC  Thyroid  Stimulating  Hormone  2™ 
International Reference Preparation 1983 80/558.
CONTENTS:
Microtitre Plate 12 * 8 Wells * 1
Breakable  wells  coated  with  specific  antibodies 
contained in a resealable foil bag with a desiccant.
Cal A 0 µ IU / ml 1 ml
Reference  Standard:  Human  serum  free  of 
TSH.Lyophilised. (Colourless)
Cal B 0.5 µ IU / ml 1 ml
Reference  Standard:  TSH  diluted  in  human  serum. 
Lyophilised. (Colourless)
Cal C 2 µ IU / ml 1 ml
Reference  Standard:  TSH  diluted  in  human  serum. 
Lyophilised. (Colourless)
Cal D 5 µ IU / ml 1 ml
Reference  Standard:  TSH  diluted  in  human  serum. 
Lyophilised. (Colourless)
Cal E 10 µ IU / ml 1 ml
Reference  Standard:  TSH  diluted  in  human  serum. 
Lyophilised. (Colourless)
Cal F 25 µ IU / ml 1 ml
Reference  Standard:  T4  diluted  in  human  serum. 
Lyophilised. (Colourless)
Conj 11 ml
TSH HRP Conjugate: TSH conjugated to Horseradish 
Peroxidase. Ready to use (Red).
Subs TMB 11 ml
Substrate Solution:3,3’,5,5’ Tetramethyl Benzidine in a 
citrate buffer. Ready to use (Colourless).
Soln Stop HCI 1M 11 ml
Stop  Solution:  Hydrochloric  acid  diluted  in  purified 
water. Ready to use (Colourless).
SPECIMEN COLLECTION AND PREPARATION:
Obtain a sample of venous blood from the patient and allow a clot to form and retract. 
Centrifuge clotted blood sample and collect clear serum. Fresh serum samples are required.
Do  not  use  haemolysed,  contaminated  or  lipaemic  serum  for  testing  as  this  will 
adversely affect the results.
Serum may be stored at 2° C to 8° C for up to 48 hours prior to testing. If  longer 
storage is required, store at -20° C for up to 1 year. Thawed samples must be mixed prior to 
testing.
Do not use Sodium Azide as a preservative as this may inhibit the Peroxidase enzyme 
system.
Do not repeatedly freeze-thaw the specimens as this will cause false results.
ASSAY PROCEDURE:
1) Bring all the kit components and the test serum to room temperature (20°C to 25°C) 
prior to the start of the assay.
2) One set of Standards should be run with each batch of test serum. Secure the desired 
number of coated wells in the holder. Record the position of the standards and the test 
serum on the EIA Data Recording Sheet provided.
3) Unused strips should be resealed in the foil bag containing the desiccant, using the 
resealing zip-lock before being replaced at 2° C to 8° C.
4) Dispense 100 µl of Standards and test serum into the appropriate wells.
5) Dispense 100 µl of Anti-TSH Conjugate into each well. Mix thoroughly for 30 seconds. 
It is very important to mix completely.
6) Incubate for 60 minutes at room temperature (20°C to 25°C).
7) Hand Washing: At the end of the incubation period, discard the contents of the wells by 
flicking plate contents into a Biohazard container. Then strike the wells sharply against 
absorbent  paper.  Ensure  adequate  disinfectant  is  contained  in  the  Biohazard 
container.
8) Fill the wells with a minimum of 300 µl of distilled water per well. Flick plate contents 
into  a  Biohazard container.  Then strike the wells  sharply against  absorbent  paper. 
Wash the empty wells 5 times.
9) Strike the wells sharply onto absorbent paper or paper towel to remove all  residual 
water droplets.
10) Machine Washing: Ensure that 300 µl of distilled water is dispensed per well and that 
an appropriate disinfectant is added to the waste collection bottle. Wash the empty well 
5 times. After washing remove excess fluid by striking the wells sharply onto absorbent 
paper or paper towel to remove all residual water droplets.
11) Dispense 100 µl Substrate Solution into each well and mix gently for 5 seconds.
12) Incubate in the dark for 20 minutes at room temperature (20°C to 25°C).
13) Stop the reaction by adding 100 µl Stop Solution to each well.
14) Gently mix for 30 seconds to ensure that the blue colour changes completely to a 
yellow colour.
15) Read the optical density immediately (no later than 10 minutes) using a microplate 
reader with a 450nm filter.
Normal TSH value – 0.5 to 5 µ units / ml
ESTIMATION OF GLUCOSE (GOD-POD METHOD, END POINT) BY 
AUTOANALYZER 
PRINCIPLE
Glucose + O2 + H2O        Glucose oxidase     Gluconic acid + H2 O2
H2 O2  + 4HBA + 4AAP    Peroxidase Quinoneimine Dye + 2 H2O  
4AAP : 4 – Aminoantipyrine
4HBA:  4 - Hydroxy benzoic acid
The intensity of the pink colour formed is proportional to the glucose concentration and 
can be measured photometrically between 500 to 540 nm.
REAGENT COMPOSITION (When reconstituted as directed)
REAGENT 1: Glucose Reagent
Glucose oxidase 20000 IU/L
Peroxidase 3250 IU/L
4-Aminoantipyrine 0.52 m m ol/L
4-Hydroxybenzoic acid 10 m m ol/L
Phosphate buffer 110 m m ol/L
Also contains non reactive fillers and stabilizers pH 7.0 ± 0.2 at 25 °C.
REAGENT 2: Glucose Standard
Glucose Standard 100 mg/dl (5.55 m m ol/L)
REAGENT RECONSTITUTION:
Allow the vial  to attain room temperature. Dissolve the contents of  each vial  using 
Glucose diluent with special lipid clearing agent. Make up the final volume of 200ml or 500ml 





Sample Volume (µl) 5 / 10
Reagent Volume(µl) 500 / 1000
Incubation time (min) 15
Incubation Temperature (° C) 37
Normal row (mg/dl) 70
Normal High (mg/dl) 110
Linearity Low (mg/dl) 0
Linearity High (mg/dl) 500
Concentration of Standard (mg/dl) 100
Blank with Reagent
Absorbance Limit (max) 0.3
Units Mg/dl
ASSAY PROCEDURE:
Pipette into tubes marked Blank Standard Test
Working Reagent 1000 µl 1000 µl 1000 µl
Distilled water 10 µl - -
Standard - 10 µl -
Sample - - 10 µl
Mix  well  and  incubate  for  15  minutes  at  37°  C.  Read  the  absorbance  of 
Standard and each sample tube against reagent blank at 505nm (500 – 540nm) or 505 / 670 
nm on bichromatic analyzer.
CALCULATION:
Absorbance of Sample
Glucose =                                               *  Concentration of standard (mg / dl)    
(mg/dl)           Absorbance of Standard
Normal Glucose values – 70 to 110 mg/dl (fasting)
ESTIMATION OF CHOLESTEROL BY ENZYMATIC METHOD
PRINCIPLE
Cholestrol Esterease
Cholesterol Ester + H2O                                            Cholesterol + Fatty Acids
                                           Cholesterol oxidase
Cholesterol + O2                                                         Cholestenone + H2O2   
Peroxidase
2 H2O2  + Phenol + 4-Aminoantipyrine                            Red quinone + 4 - H2O
The concentration of cholesterol in the sample is directly proportional to
the intensity of the red complex (Red Quinone) which is measured at 500 nm.
REAGENTS:
Reagent 1 (Enzymes / Chromogen) : 
Cholesterol Esterase ≥ 200 U/L
Cholesterol Oxidase ≥ 250 U/L
Peroxidase ≥ 1000 U/L
4 – Aminoantipyrine 0.5 mmol/L
 
Reagent 1A (Buffer):
Pipes buffer , pH 6.90 50 mmol/L
Phenol 24 mmol/L
Sodium Cholate 0.5 mmol/L
Standard  (Cholesterol 200 mg/dl):
Cholesterol 2 g/L
REAGENT RECONSTITUTION:
Allow the reagents to attain room temperature. Dissolve the contents of one bottle of 
reagent 1 with one bottle of reagent 1A. Mix by gently swirling.
Write the Reconstitution date in the space provided on the label of bottle 1A. Wait for 5 
minutes before using.
PROCEDURE:
The Samples and the reconstituted reagent should be brought to room temperature 
prior to use. The following general system parameters are to be used with this kit.
General System Parameters
Reaction Type : Endpoint
Reaction Stope : Increasing
Wavelength : 500 nm (492-550)
Flowcell Temp : 30°C
Incubation : 5 min at 37°C
Sample Vol : 10 µL
Reagent Vol : 1.0 mL
Std. Concentration : 200 mg/dL
Zero Setting with : Reagent Blank
Set the instrument using above system parameters.
Dispense into test tubes:
Blank Standard Test
Reconstituted Reagent 1 mL 1 mL 1 mL
Standard - 10 µL -
Sample - - 10 µL
Incubate for 5 minutes at 37°C. Mix and read.
Normal Cholesterol Values – 150 to 260 mg/dl
ESTIMATION OF HDL-CHOLESTEROL BY PHOSPHOTUNGSTATE METHOD
PRINCIPLE
Chylomicrons,  VLDL  (Very  Low  Density  Lipoproteins)  and  LDL  fractions  in 
serum or plasma are separated from HDL by precipitating with Phosphotungstic Acid and 
Magnesium Chloride. After centrifugation, the cholesterol in the HDL fraction, which remains 
in the supernatant is assayed with enzymatic cholesterol method, using Cholesterol Esterase, 
Cholesterol Oxidase, Peroxidase and the chromogen 4-Aminoantipyrine/Phenol.
REAGENTS:
Reagent 1 (Enzymes / Chromogen) : 
Cholesterol Esterase ≥ 200 U/L
Cholesterol Oxidase ≥ 250 U/L
Peroxidase ≥ 1000 U/L
4 – Aminoantipyrine 0.5 mmol/L
 
Reagent 1A (Buffer):
Pipes buffer , pH 6.90 50 mmol/L
Phenol 24 mmol/L
Sodium Cholate 0.5 mmol/L
Reagent 2 (Precipitating Reagent):
Phosphotungstic Acid 2.4 mmol/L
Magnesium Chloride 39 mmol/L
Standard (HDL  Cholesterol 50 mg/dL):
Cholesterol 0.5 g/L
PROCEDURE:
The samples, the precipitating reagent 2 and the reconstituted reagent should 
be brought to room temperature prior to use.
PRECIPITATION:
Dispense into Centrifuge Tube:
Test
Sample 0.20 mL (200 µL)
Precipitating Reagent 2 0.20 mL (200 µL)
Mix well. Centrifuge at 1500g or 3500-4000 rpm for 10 min. Separate the clear supernatant 
immediately and determine the cholesterol content .
Dispense into test tubes:
Blank Standard Test
Reconstituted Reagent 1 mL 1 mL 1 mL
Standard - 20 µL -
Supernatant - - 20 µL
Incubate for 5 minutes at 37°C. Mix and Read.
Normal HDL Values – 30 to 70 mg/dl
ESTIMATION OF TRIGLYCERIDES –GPO METHOD
PRINCIPLE
Enzymatic determination to Triglycerides by the following reaction
Triglycerides    Lipase              Glycerol
          +                    +
         O              Fatty acids
Glycerol       Glycero kinase            Glycerol-3-phosphate
      +                                                 +
          ATP              ADP
     Glycerol-3-Phosphate         Glycerol-Phosphate    H2O2 +Dihydroxy
+     oxidase         acetone Phosphate
O2
     H2O2 + 4 Aminoantipyrine Peroxidase    Coloured complex
+   +
                 DHBS                                                                     3 H2 O
     The intensity of coloured complex produced is directly proportional to the concentration of 
Triglycerides content, which is measured at 520 nm (505-530) nm or with Green filter.
SPECIMEN COLLECTION:
Fresh, clear, fasting unhemolysed serum is preferred although. Plasma prepared with 
anticoagulants, such as heparin, citrate may be used.
GENERAL PROCEDURE:
Type of reaction : End Point
Sample Volume : 10 microliters (0.01 ml)
Working reagent volume : 1.0 ml
Wavelength : 520 nm (505-530) nm
Flowcell Temperature : 30°C
Incubation : 10 min at  37°C
Light path : 1.0 cm
Set Zero with : Reagent blank
PROCEDURE FOR 2.5 ML CUVETTE CAPACITY:
Blank Standard Test
Working Reagent (ml) 1.0 1.0 1.0
Standard (ml) - 0.02 -
Sample (ml) - - 0.02
Mix and incubate at 37°C for 10 minutes
Distilled water (ml) 1.5 1.5 1.5
 Mix and read the Absorbance of Standard and test against Reagent blank at 520 
nm (505-530nm) or with Green filter, within 30 minutes.
TEST RESULTS:
Triglycerides concentration =     Absorbance of test              X   200
                mg/dl Absorbance of Standard
Normal TGL Level values – 65 to 170 mg/dl
RESULTS AND DISCUSSION
In our study 60 individuals with IDDM  (Male 32, Female 28 in the age group of 10 to 
35 years were selected.) Based on the level of anti TPO antibody T3,T4,TSH and lipid profile 
the biochemical parameters were tabulated, statistically analyzed and evaluated.
In this study 16 persons shows high levels of anti TPO Ab greater than 40 IU. Out of 
this 10 persons are female and 6 are males (Table-1).
T3 levels were low in 5 persons in anti TPO Ab Positive Individuals (31.3%) (Table 2) 
(Chart 3).
T4 levels were low in 6 persons (37.5%) (Table-3) (Chart 2).
TSH levels high in 9 persons (56.3%) (Table-4) (Chart 4).
The value of high TSH statistically significant according to the Pearson R formula P < 
0.001.
There is no correlation between duration of IDDM and anti TPO Ab level (Table -7).
There is no statistical  correlations between high anti  TPO Ab titer and Lipid profile 
(Table-8).
There is significant correlation between Age and anti TPO Ab level as per the T-Test P 
< 0.049 (Table-9).
Statistical correlation between BMI and TPO Positive and Negative levels is significant 
P < 0.001 (Table-10) (Chart 1).
The correlation between weight and TPO Positive and Negative levels is significant in 
T-Test P < 0.001 (Table-11).
Table-12 shows overall  correlation between TPO, Age,  Duration of  the Disease,  Blood –
Sugar level and BMI.
There is no significant correlation between Blood-Sugar level and TPO level.
Athero Genic index (log ( Tgl / Hdl in m/mol) ). The Athero Genic index in TPO positive 
individuals in this study were raised in 10 persons (Table-13).
Correlation between T3,T4,TSH and BMI, Weight shows there is significant correlation 
present.
Prevalance of TPO-Ab with 95% CI is   p ± 1.96 √ 0.267 * 0.733 / 60
23 to 30. Our value is 26.7 %
DISCUSSION
Auto immune mechanisms are involved in many cases of Type-1 DM (1). The 
role of screening for thyroid levels in Type-1 DM is controversial. Substantial prevalence of 
thyroid abnormalities were noted in patients with Type-1 diabetes mellitus -1 (3),(6)  ,(36), 
(37). The mean age of diagnosis 19 ± 2 in Type 1 diabetes mellitus and 29 ± 3 years. Hypo 
thyroidism was more common in females than males. Patients who were TPO positive were 
17.91 times as likely to develop hypo thyroidism. This statement correlates with our study. 
There were no differences in BMI and lipid profile (4).
Our results indicate that all Type-1 diabetic individuals should undergo annual 
screening  of  serum  TSH  measurement  to  detect  asymptomatic  thyroid  dysfunction  with 
positive TPO individuals. In Type-1 diabetes 21.6 % has high level of antibodies to TPO, TG. 
Thyroid autoimmunity was more common in girls and this predominance was absorved in all 
age groups (5),(24),(25). In a study to detect sub-clinically associated AITD. 22 % of patients 
shows thyreopathy with the assessment of thyroid auto antibodies and TSH. 
The screening for auto antibodies in Type-1 diabetic patients will  reveal sub-
clinical  cases of  AITD.  The sub-clinical  thyroid  dysfunction have no influence on diabetic 
control. There is a need for regular follow up of patients with positive auto antibodies to detect 
further deterioration of other organs(6), (12), (14).
In  Type-1  DM  Patients  with  thyroid  abnormalities  have  shown  that  thyroid 
volume is increased ultra sonographicaly. The expression of involvement of the thyroid in an 
auto immune disorder is not limited to the islet cells (7),(17). In a study on AITD anti-TPO and 
anti-TG level have increased more in girls than boys. For early detection of auto immune 
thyroidties in children with measurement of anti TPO and TSH in a yearly intervals after the 
age of 12 is recommended (8),(9).
A study of thyroid antibodies and TSH level of first degree relatives of Type-1 
DM patients and in Anti TPO – Ab positive relatives shows that TSH basal levels were at the 
upper limit. The TSH level after seven years were increased to 3.6 ± 1.9. The subjects with
TPO – Ab positivity which shows thyroid auto immunity with TPO – Ab positivity to have be 
tested regularly on long term basis not only diabetic patients but also in their first degree 
relatives, in siblings / children (10). AITD are common in adolescents with Type-1 DM. 
Seventy patients were performed ultra sonogram of thyroid and TSH measured 
in 62 persons. TgAb, TPO-Ab levels were estimated  in 51 patients. TPO-Ab was found to be 
increased in 13.7% patients. TgAb slightly increased. US reveals 9 patients having AITD 18% 
shows hypo echogenicity. There is no correlation between duration of Type-1 diabetes and 
TPO – Ab (12).
The  use of  high  sensitive  immuno metric  methods  in  clinical  laboratories  to 
assay anti thyroid anti bodies expanded in recent years. The agreement of qualitative results 
is close to 97% for anti-TPO (13). In individual with Type-1 DM the measurements of anti 
TPO-Ab, TSH are the most efficient and cost effective combination of screening test in the 
early detection of AITD. 
The positive predictive value of (anti TPO-Ab and TSH is 90%).  In our study 
there is increased level of anti TPO-Ab and increased level of TSH are noted and low T4 and 
T3 level indicating sub clinical hypo thyroidism (14),(35),(36).
In a three years follow up of study of Type-1 DM there is prevalence of thyroid 
dysfunction increased from 5 to 8 %. The prevalence of TPO – Ab is unchanged. All Type-1 
DM patients with increased TSH level has US abnormalities while US abnormalities were not 
always  associated  with  increase  in  TSH  level.Thyroid  ultra  sound  abnormalities  was  a 
sensitive but  non specific  marker  of  auto immune thyroid  diseases.  This  shows that  it  is 
unsuitable for screening purposes.
 So we recommend regular annual screening of serum TSH in the follow up of 
young Type-1 DM (16). Sub clinical phase of thyroid dysfunction in Type-1 diabetes due to 
auto antibody positivity did not affect control  of diabetes while fully manifested hyper , hypo 
thyroidism impair diabetes control. So there is no influence on diabetic control. 
In our study fasting blood glucose level in cases with positive TPO – Ab did not 
reveal  statistical  significance  (19,(20).  We recommend  regular  follow  up  of  patients  with 
positive  anti  TPO-Ab  antibody  titer  to  prevent  further  deterioration  of  other  organs  (i.e., 
thyroid. Hypo thyroidism and its impairment of DM control)
In this study athero genic index log (TGL / HDL ) m/mol of TPO positive and 
TPO negative individuals shows that there is no statistical 
significance 10 / 16  (38),(39).
 
There is inverse correlation between serum TSH level and serum T3,T4 i.e., T3, 
T4 levels are reduced and TSH is raised .  Which indicates sub clinical  hypo thyroidism. BMI 
was calculated and it correlates between TPO – Ab titer. Weight also correlates with the TPO 
– Ab titer. So sub clinical auto immune thyroid function which is responsible for the weight 
gain and BMI increase
.
CONCLUSION
Type-I  DM  being  a  chronic  auto  immune  disease  which  is  associates  with 
different auto-anitbodies to thyroid, viz, anit TPO-Ab, anti TGAb and anti thyroid antibodies.
Thyro  peroxidase  being  responsible  for  iodination  of  thyrosine  moieties, 
responsible for active thyroid hormone T4 and T3 synthesis, when inhibited by anti TPO Abs 
decreases  the  active  T4  ,T3  synthesis  resulting  in  low  T4,  T3  level  and  there  is  a 
compensatory increase in TSH level, which with increased anti TPO tier and duration leads to 
deterioration of thyroid function from sub clinical dysfunction to fully manifest clinical hypo 
thyroidism. 
Anti  TPO-  Abs  being  the  autoimmune  parameter  measured  in  Type-1  DM 
patients. In our study it is characterised by low T4 and T3 levels and increased TSH level.
While in a study it was found anti TPO-Ab with anti TG Abs  may present with thyro 
toxicosis. Similarly anti thyroid Abs in Type-1 DM patients leads to thyro toxicosis.
In this study TPO – Ab were measured. All  the cases of TPO – Ab positive 
individuals show sub clinical hypo thyroidism with elevated level of TSH. So annual screening 
of TSH is essential to detect  and prevent further deterioration into clinical hypo thyroidism 
and follow up. 
Type-1 DM is an auto immune disorder which affects pancreatic beta cell and 
other  endogenous  involvement  is  in  not  only  to  pancreas  but  also  to  the  other  organs 
(Thyroid, Adrenals and non endocrine organs like GI mucosa with Hypo, Hyper thyroidism, 
Addison’s diseases, celiac disease). 
There is mean latent period of 10 years between the onset of Type-1 DM and 
thyroid disease. During which sub-clinical thyroid dysfunction turns into clinical hypo function. 
So annual  screening  of  TSH level  is  recommended in  anti  TPO positive  individuals  with 
Type-1 DM.
AITD also has influence on DM control because hypo or hyper thyroidism will 
affect the diabetic control while sub-clinical hypo thyroidism has no effect on diabetic control. 
In  anti  TPO positive  Type-1  DM patients  estimation  of  TSH level  raise  should  be  done 
annually,  in  order  to  detect  hypo function of  thyroid  ,  even in sub clinical  itself  so as to 
maintain Euglycemic status.
In reference 20, based on study of 237 diabetic children the authors proposed 
the following screening protocol.
1) Thyroid dysfunction coexisted with Type-1 DM in 5.5% of their  
                          cohort but not with Type-2 DM.
2) Screening for fT4 and TSH levels identifies asymptomatic    
                          children.
3) Thyroid dysfunction was strongly associated with thyroid   
                          auto-antibodies.
4) Thyroid function should be assessed annually in diabetic  
                          children.
Based on their study the author recommend that 
1) fT4 and TSH level should be measured at diagnosis and  
                          annually thereafter.
2) Thyroid auto – antibodies should be measured at diagnosis of  
                          Type-1 DM and should be repeated if TSH level exceeded  
                          the reference range.
While the other studies suggest , Type-1 DM young patients with anti TPO Abs 
develop clinical  thyroid disease with a mean latent interval of 10 years from the onset of 
Type-1 DM, during which sub clinical thyroid dysfunction occurs and it should be suffice to 
measure TSH level annually in anti TPO positive Type-1 DM patients with which we concur.
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